期刊文献+

白藜芦醇对不同条件下骨损伤的影响及相关机制 被引量:4

Effect of resveratrol on bone injury under different conditions and its mechanism
下载PDF
导出
摘要 白藜芦醇是一种非黄酮类多酚化合物,具有抗炎、抗氧化、抗衰老、调节免疫等多种生物学活性,被广泛应用于多种疾病的研究。白藜芦醇能促进成骨细胞的分化和矿化,并能抑制破骨细胞的形成和骨吸收功能。白藜芦醇对炎症、香烟烟雾、颗粒诱导及雌激素缺乏等造成的骨损伤具有保护作用,但不同剂量的白藜芦醇对化疗状态下的骨损伤可能有不同的影响。本研究主要综述白藜芦醇对多种不同条件下骨及骨组织细胞的影响及作用机制,为白藜芦醇作为临床治疗相关疾病药物的安全性及有效性提供依据。 Resveratrol is a non-flavonoid polyphenol compound, possessing many biological activities such as anti-inflammatory, anti-oxidation, anti-aging, immune regulation and so on. It is widely used in the study of many diseases. Resveratrol can promote the differentiation and mineralization of osteoblasts, inhibit the formation of osteoclasts and bone resorption. Resveratrol has protective effects on bone in the state of inflammation,cigarette smoke, particle induction and estrogen deficiency, but different doses of resveratrol have different effects on bone in the state of chemotherapy. The effects and mechanism of resveratrol on bone and bone tissue cells under different conditions were summarized, which provided a basis for the safety and effectiveness of resveratrol as a drug for clinical treatment of related diseases.
作者 张倩 韩婕 汤旭磊 Zhang Qian;Han Jie;Tang Xu-lei(Department of Endocrinology,The First Hospital of Lanzhou University,Lanzhou 730000,China)
出处 《兰州大学学报(医学版)》 CAS 2020年第3期23-27,共5页 Journal of Lanzhou University(Medical Sciences)
基金 甘肃省科技计划项目(144FKCA075)。
关键词 白藜芦醇 骨髓间充质干细胞 成骨细胞 破骨细胞 resveratrol bone bone marrow mesenchymal stem cell osteoblast osteoclast
  • 相关文献

参考文献2

二级参考文献43

  • 1肖本熙,黄忆明.白藜芦醇对去卵巢大鼠骨密度的影响[J].营养学报,2005,27(6):510-513. 被引量:7
  • 2Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: Anovelsecreted protein involved in the regulation of bone density[J]. Cell, 1997,89(2) :309 - 319.
  • 3Lacey DL,Timmes E,Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulats osteoclasts differentiation and activation[J]. Cell, 1998,93(2):165- 176.
  • 4Greenfield EM, BI Y, Miyauchi A. Regulation of osteoclast activity[J]. Life Sei, 1999,65(11):1087- 1099.
  • 5Bhat K,I.antvit D,Christov K, et al. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models[ J]. Cancer Res, 2001,61 (20) : 7456 - 7463.
  • 6朱鋐达.骨质疏松症的分子生物学进展[M]//罗敏.分子内分泌学.北京:人民军医出版社,2003:251-261.
  • 7Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenes-inhibitory factor and is identical to TRANCE/ RANKL[J]. Proc Nat Acad Sci USA, 1998,95(7):3597 - 3602.
  • 8Eghbah-Fatoumehi G, Khosla S, Sanyal A, et al. Role of rank hgand in mediating increased bone resorption in early postmenopausal women[ J]. J Clin Invest, 2003,111 (8) : 1120- 1122.
  • 9Silva I and Branco JC. Denosumab: recent update in postmenopausal osteo- porosis. Acta Reumatol Port 2012, 37:302-313.
  • 10Yilmaz M, Isaoglu U, Uslu T, Yildirim K, Seven B, Akcay F and Hacimufluoglu A. Effect of methylprednisolone on bone mineral density in rats with ovariectomy-induced bone loss and suppressed endogenous adren- aline levels by metyrosine. Indian J Pharmaco12013, 45: 344-347.

共引文献79

同被引文献45

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部